Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Date publication

septembre 2018

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr FEUGIER Pierre

Tous les auteurs :
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30184451

Résumé

Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Disease-Free Survival, Female, Humans, Intention to Treat Analysis, Lenalidomide, Lymphoma, Follicular, drug therapy, Male, Middle Aged, Neutropenia, chemically induced, Rituximab, administration & dosage, Skin Diseases, chemically induced, Survival Rate, Thalidomide, administration & dosage

Référence

N. Engl. J. Med.. 2018 09 6;379(10):934-947